Levaquin

Top-Selling Drugs About to Lose Patent Protection

The pharmaceutical industry is about to fall off a cliff -- a patent cliff. Over the next few years, some of the world's most popular and lucrative medicines will go off patent, and generic competition will siphon an estimated quarter of a trillion dollars from companies' bottom lines. Here's a rundown:

Ortho Ordered to Pay $1.7 Million in Levaquin Lawsuit

On Wednesday, a Minneapolis jury ordered Johnson & Johnson subsidiary Ortho-McNeil-Janssen Pharmaceuticals to pay an 87-year-old man $1.7 million because its antibiotic Levaquin damaged his Achilles tendons. It was the first verdict from about 2,600 similar lawsuits filed so far.